ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50-Day Moving Average – Here’s What Happened

Posted by Stanley Muller on Sep 10th, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR – Get Free Report)’s share price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.92 and traded as high as $2.11. ProQR Therapeutics shares last traded at $2.05, with a volume of 449,152 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PRQR shares. JonesTrading lowered their price target on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. HC Wainwright restated a “buy” rating on shares of ProQR Therapeutics in a report on Monday, August 17th. Chardan Capital reduced their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Check Out Our Latest Report on PRQR

ProQR Therapeutics Stock Performance

The company has a 50-day moving average of $1.93 and a 200-day moving average of $1.75. The firm has a market capitalization of $204.40 million, a price-to-earnings ratio of -4.22 and a beta of 0.06.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. As a group, analysts anticipate that ProQR Therapeutics N.V. will post -0.45 EPS for the current fiscal year.

Insider Transactions at ProQR Therapeutics

In other news, CEO Daniel de Boer purchased 150,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were purchased at an average price of $1.74 per share, with a total value of $261,000.00. Following the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at $522,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction dated Friday, July 17th. The shares were purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares of the company’s stock, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 600,000 shares of company stock valued at $988,500. Corporate insiders own 8.40% of the company’s stock.

Institutional Trading of ProQR Therapeutics

Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd grew its position in ProQR Therapeutics by 1,057.4% in the fourth quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 107,713 shares in the last quarter. Quadrature Capital Ltd boosted its stake in shares of ProQR Therapeutics by 188.4% during the 4th quarter. Quadrature Capital Ltd now owns 104,231 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 68,091 shares during the last quarter. Persistent Asset Partners Ltd grew its holdings in shares of ProQR Therapeutics by 24.5% in the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 8,874 shares in the last quarter. Simplex Trading LLC increased its position in shares of ProQR Therapeutics by 44,169.0% in the fourth quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 44,169 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in ProQR Therapeutics by 73.9% during the fourth quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 36,087 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.